Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience
EC Chen, W Gibson, P Temoczko, NT Connell… - …, 2023 - Wiley Online Library
Abstract Introduction Acquired haemophilia A (AHA) is a rare and potentially life‐threatening
bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII) …
bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII) …
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience
EC Chen, W Gibson, P Temoczko… - … : the official journal …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Acquired haemophilia A (AHA) is a rare and potentially life-threatening bleeding
disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII). Treatment …
disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII). Treatment …
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience.
EC Chen, W Gibson, P Temoczko, NT Connell… - …, 2023 - search.ebscohost.com
Abstract Introduction: Acquired haemophilia A (AHA) is a rare and potentially life‐
threatening bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII …
threatening bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII …
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience.
EC Chen, W Gibson, P Temoczko… - … : the Official Journal of …, 2022 - europepmc.org
Methods We present a retrospective report of 11 AHA patients treated with emicizumab, a
FVIII-mimetic bispecific antibody, administered at 3 mg/kg weekly for 4 weeks in conjunction …
FVIII-mimetic bispecific antibody, administered at 3 mg/kg weekly for 4 weeks in conjunction …